Biotech entity
All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention AMVUTTRA, the most common co-covered peer. We currently track 1 Biotech story that mention Alnylam Pharmaceuticals, all published on August 31, 2026.
Last mentioned: Aug 31, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention AMVUTTRA, the most common co-covered peer. We currently track 1 Biotech story that mention Alnylam Pharmaceuticals, all published on August 31, 2026. Each carries 3 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 1 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Alnylam Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Late-breaking oral presentation at ESC Congress 2026
Alnylam presented a prespecified HELIOS-B subgroup analysis of vutrisiran according to baseline tafamidis use in 654 randomized and treated patients.
Simultaneous publication in Journal of the American College of Cardiology
The HELIOS-B subgroup findings were published concurrently with the ESC Congress presentation.
Alnylam's HELIOS-B subgroup analysis at ESC 2026 supports RNAi-based vutrisiran as a consistent treatment across ATTR-CM patients, including 40% already on tafamidis, while zilebesiran expands the RNAi cardiovascular pipeline.
Source: Finanznachrichten.de · Financialcontent
Alnylam Pharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
